THE US Food and Drug Administration has approved the first drug for the treatment of neurotrophic keratitis, a rare disease affecting the cornea.
Oxervate (cenegermin) is a topical eye drop which was granted priority review designation as well as being listed as an orphan drug.
FDA spokesman Wiley Chambers said while the prevalence of the condition was low, the impact for an individual could be devastating.
"Today's approval provides a novel topical treatment and a major advance that offers complete corneal healing for many patients."
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Aug 18
